Core Viewpoint - China Life Insurance announced that by November 30, 2025, the company's total premium income is expected to exceed RMB 700 billion [1] Group 1 - The premium data is based on the "Accounting Standards for Enterprises No. 25 - Original Insurance Contracts" and "Accounting Treatment Regulations Related to Insurance Contracts," and it is unaudited [1] - The company will disclose the audited total premium data for the year ending December 31, 2025, in its annual report [1]

近期，金融监管总局披露了两则任职资格批复文件：一是《关于陈英杰中国太平洋人寿保险股份有限公 司首席合规官任职资格的批复》，核准了陈英杰出任太保寿险首席合规官；二是《关于马征中国人寿养 老保险股份有限公司首席合规官任职资格的批复》，核准了马征担任国寿养老首席合规官。 事实上，这只是今年险企合规管理体系建设提速的一个缩影。据《金融时报》记者梳理，截至目前，年 内已有十余家保险公司、保险资产管理公司及相关机构的首席合规官任职资格获得核准，合规管理进程 全面提速。 从具体情况来看，年内履新名单覆盖全国多地监管辖区及各类保险相关机构： 首席合规官岗位之所以密集落地，直接源于监管层面的制度要求。去年12月，金融监管总局发布《金融 机构合规管理办法》，要求金融机构应当在机构总部设立首席合规官。该办法适用于保险公司（包括再 保险公司）、保险资产管理公司、保险集团（控股）公司、相互保险组织等机构，并于2025年3月1日起 施行。 根据监管要求，首席合规官应当组织合规管理部门对金融机构发展战略、重要内部规范、重要新产品和 新业务方案、重大决策事项进行合规审查，并出具书面合规审查意见；发现金融机构及其员工存在重大 违法违规行为或者 ...

★ 宏观动态 ★ 财政部拟发行2025年记账式附息（二十四期）国债，竞争性招标面值总额1045亿元 财政部拟发行2025年记账式附息（二十四期）国债。本期国债为2年期固定利率附息债。本期国债竞争性招标 面值总额1045亿元，进行甲类成员追加投标。本期国债票面利率通过竞争性招标确定。本期国债自2025年12月 15日开始计息，每年支付利息，付息日为每年12月15日（节假日顺延，下同），2027年12月15日偿还本金并支 付最后一次利息。招标时间为2025年12月12日上午10:35至11:35。 高市早苗就自民党支部违规收受捐款道歉 据央视新闻，当地时间12月9日，日本首相、自民党总裁高市早苗表示，就自己担任代表的自民党支部违规收 受来自企业的捐款一事表示道歉。 日本神户学院大学教授上脇博之4日向检察机关控告，高市早苗涉嫌违规收受企业的政治捐款。根据控告文 件，高市担任代表的"自民党奈良县第2选举区支部"2024年从东京都一家企业处收受了1000万日元捐款（约合 45万元人民币）。但根据日本《政治资金规正法》，该企业按其注册资本规模全年可捐款上限为750万日元。 受到控告的包括高市本人、其所属支部的会计负责人以 ...

来源：险联社 原标题：连自家代理人都"坑"？这家保险公司被判赔30万重疾险理赔金 最近中国裁判文书网公布了一则重疾险纠纷的案例，原告一方是中国人寿的保险代理人，被告则是中国 人寿山东分公司。 最后法院一审判中国人寿山东分公司败诉，赔付30万重疾险理赔。 这狠起来，连自己家代理人都"坑"？ 2020年3月，做保险销售的付某霞给自己家不到1岁的女儿投保了《国寿康宁少儿重大疾病保险》及附加 险《国寿附加康宁少儿两全保险》《国寿附加国寿福豁免保险费重大疾病保险（至尊版）》等保险。保 险金额均为30万元，保险期间为30年，交费方式为年交，销售人员就是付某霞自己。 付某霞交纳上述保险的4期保费，合计12600元。 今年2月，付某霞不到6岁的女儿在山东滨州医学院附属医院住院期间被诊断为"1型糖尿病、糖尿病性酮 症酸中毒"，并连续使用胰岛素至今。 付某霞于是向中国人寿保险山东分公司申请理赔，结果被拒了。 保险公司认为付某霞女儿的疾病并未达到重大疾病保险条款约定的重疾条件： 1、付某霞女儿确定疾病是1型糖尿病、糖尿病性酮症酸中毒，该病情目前并未达到重大疾病保险条款约 定的重疾条件，因此不能支付保险金。 2、付某霞作为保险合同的 ...

Group 1 - Wanma Technology has been pre-awarded a total of 59.9434 million yuan for multiple State Grid projects, which accounts for 14.49% of its latest audited main business revenue [1] - Tianen Kang's subsidiary received a drug registration certificate for Methimazole tablets, a medication used for hyperthyroidism [2] - Taijing Technology invested 10 million yuan to establish a special fund focused on high-speed network communication chips [3] Group 2 - Youyou Foods plans to use 10 million yuan of its own funds to purchase principal-protected financial products with an expected annual yield of 0.5%-5.0% [4] - Yangfan New Materials announced the release of detention measures against its controlling shareholder, allowing him to resume his duties [5] - Xianju Pharmaceutical received approval for a supplementary application for Nicardipine injection, a calcium channel blocker used for acute hypertension [6] Group 3 - Jingu Co. plans to repurchase shares worth 30-60 million yuan for employee stock ownership plans or equity incentives [7] - Double Tower Foods' Thai subsidiary has completed the construction of its production line and is in the initial production phase [8] - Tongyi Zhong intends to invest approximately 198 million yuan in a project for the industrialization of ultra-high molecular weight polyethylene fibers [9][10] Group 4 - Zhangyue Technology received a dividend of 4.99 million yuan from its stake in Dianzhong Technology, which represents 10.12% of its audited net profit for 2024 [11] - Sihua Electronics announced the resignation of its general manager due to job transfer, with the current manager continuing until a new one is appointed [12] - Jiutian Pharmaceutical's new drug JMHT06 has received approval for clinical trials for acute gouty arthritis [13] Group 5 - Anlian Ruishi has established a joint venture for embodied intelligent robots with a registered capital of 20 million yuan [14] - Kelin Electric's application for a private placement has been accepted by the Shanghai Stock Exchange [15] - Guoyao Modern's subsidiary has received approval for the listing of Agomelatine raw materials, used in antidepressant synthesis [16] Group 6 - Xintiandi's application for the listing of Ferrous Fumarate raw materials has been approved, which is used for treating iron deficiency anemia [17] - ST Weihai, as the leading party, won a bid for a smart agriculture project worth 652 million yuan, accounting for 26.27% of its 2024 audited revenue [18] - Tian Youwei plans to purchase 100% of Krämer Automotive Systems for 1 million euros [19] Group 7 - Guangdong Yuedian A's subsidiary has successfully put into operation the third unit of its Dapu Power Plant project [20] - China Life's total premium exceeded 700 billion yuan as of November 30, 2025 [21] - Shoukai Co. achieved a total signed amount of 15.988 billion yuan in the first 11 months of 2025 [22] Group 8 - Kehua Bio's subsidiary has obtained a medical device registration certificate for an automatic chemiluminescence immunoassay analyzer [23] - Chengyi Pharmaceutical received a drug registration certificate for Torasemide tablets, which have passed the consistency evaluation [24] - Chongqing Construction won a bid for a municipal engineering project worth approximately 1.714 billion yuan [25] Group 9 - Hanjian Heshan signed a procurement contract for pipes worth 388 million yuan [26] - Jiuzhou Pharmaceutical plans to use up to 1 billion yuan of idle raised funds for cash management [27] - Xinwufeng reported an 80.97% year-on-year increase in pig sales in November 2025 [28] Group 10 - Luoniushan reported a 13.57% year-on-year increase in pig sales revenue in November 2025 [29] - Fushilai received a drug registration certificate for Alpha-Lipoic Acid tablets, used for diabetic neuropathy [30] - Dizhe Pharmaceutical presented research data on two innovative drugs at the 67th American Society of Hematology conference [31] - David Medical's subsidiary received two medical device registration certificates for single-use gastric tubes and electronic ureteral endoscope catheters [32]

该公司表示，着眼下一步发展，将坚持以客户为中心，深入贯彻"333"战略要求，践行"三坚持""三提 升""三突破"经营思路，更加注重效益优先，更加注重长期理念，更加注重资负联动，更加注重防范化 解风险，平稳推进全年业务发展，努力实现"十四五"圆满收官。 北京商报讯（记者 胡永新）中国人寿保险股份有限公司（以下简称"中国人寿"）12月9日发布信息显 示，截至2025年11月30日，该公司总保费超过7000亿元，较2024年全年总保费规模实现新的突破。 ...

Core Viewpoint - China Life Insurance has achieved a significant milestone by surpassing 700 billion yuan in total premiums by November 30, 2025, becoming the first life insurance company in China to reach this scale, marking a new chapter in its development history [1]. Group 1: Historical Development - From 1949 to 1996, China Life Insurance began its journey with the establishment of the People's Insurance Company of China, reaching a premium income of 192 million yuan in 1996, becoming the first life insurance company in China to exceed 10 billion yuan in premiums [7]. - Between 1996 and 2002, the company completed its restructuring and achieved a premium income of 128.8 billion yuan in 2002, marking its first milestone of 100 billion yuan in premiums [8]. - From 2003 to 2007, China Life successfully went public, raising 3 billion USD in its IPO, and achieved a premium income of 196.6 billion yuan in 2007, nearing the 200 billion yuan target [9]. Group 2: Recent Performance and Achievements - In the period from 2021 to 2025, China Life Insurance faced challenges in the insurance industry but managed to cross the 600 billion to 700 billion yuan threshold by November 2025, demonstrating resilience and strong adaptability [18]. - As of the third quarter of 2025, China Life achieved a new record with a new single premium of 218.03 billion yuan, a year-on-year increase of 10.4%, and a net profit of 167.8 billion yuan, up 60.5% year-on-year [28]. - The company maintained a solvency adequacy ratio of 137.5% and a comprehensive solvency adequacy ratio of 183.94%, reflecting its strong financial health [30]. Group 3: Strategic Initiatives - China Life has continuously adapted its sales channels, enhancing its agent system and focusing on professional capabilities to maintain its market leadership [19]. - The company has implemented a series of reforms, including the "Dingxin Project" in 2019, to optimize its organizational structure and improve operational efficiency [17]. - In response to the aging population and increasing demand for health and retirement services, China Life has expanded its product offerings, including health insurance and retirement products, to meet diverse customer needs [24][25].

每经AI快讯，12月9日，中国人寿公告称，截至2025年11月30日，公司总保费超7000亿元。该保费数据 为相关会计准则下数据，且未经审计。公司将在2025年年度报告中披露经审计的截至2025年12月31日止 年度的总保费数据。 ...

上述保费数据为《企业会计准则第 25 号—原保险合同》（财会〔2006〕 3 号）及《保险合同相关会计处理规定》（财会〔2009〕15 号）下数据，且 未经审计。本公司将在 2025 年年度报告中披露经审计的截至 2025 年 12 月 31 日止年度的总保费数据。 特此公告 中国人寿保险股份有限公司董事会 2025 年 12 月 9 日 证券代码：601628 证券简称：中国人寿 编号：临 2025－044 重要提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中国人寿保险股份有限公司 关于总保费逾人民币 7,000 亿元的公告 截至 2025 年 11 月 30 日，本公司总保费超过人民币 7,000 亿元。 ...

智通财经APP讯，中国人寿(601628.SH)发布公告，截至2025年11月30日，公司总保费超过人民币7000亿 元。 ...